Grifols

Grifols is a global healthcare company founded in 1909, committed to improving the health and well-being of people worldwide.
We are leaders in plasma-derived medicines and transfusion medicine, developing, producing, and providing innovative healthcare services and solutions in more than 110 countries.

Patient needs—along with our growing understanding of many chronic, rare, and prevalent diseases, some of which are very serious—drive our innovation in developing plasma-derived medicines and other biopharmaceutical products that improve people’s quality of life.

Grifols’ treatments address conditions across a wide range of therapeutic areas: immunology, hepatology, intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols operates the world’s most diversified network of donation centers, with over 400 locations across North America, Europe, Africa, and the Middle East, as well as in China through a partnership with Shanghai RAAS.

Grifols is committed to a sustainable business model that serves as a benchmark for continuous innovation, quality, safety, and ethical leadership.